Goodwin, S&C Steer Up-To $785M Sale Of ADHD Drug
Goodwin Procter LLP-advised Collegium Pharmaceutical Inc. unveiled plans Thursday to acquire attention deficit hyperactivity disorder drug Azstarys from Sullivan & Cromwell LLP-led Corium Therapeutics Holdings LLC for up to $785 million....To view the full article, register now.
Already a subscriber? Click here to view full article